Study of HPN424 in Patients With Advanced Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/6/2018
Start Date:July 31, 2018
End Date:December 2020
Contact:Harpoon Therapeutics
Email:HPN4241001@harpoontx.com
Phone:1-650-689-1047

Use our guide to learn which trials are right for you!

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

An open-label, Phase 1, study of HPN424 as monotherapy to assess the safety, tolerability and
PK in patients with advanced prostate cancer refractory to androgen therapy


Key Inclusion Criteria:

1. Male patients ≥18 years of age

2. Histologically or cytologically confirmed adenocarcinoma of the prostate

3. Progressive metastatic castrate-resistant prostate cancer (mCRPC): a) serum
testosterone levels less than 50 ng/dL (or ≤0.50 ng/mL or 1.73 nmol/L) within 28 days
prior to start of study drug, b) radiographic evidence of metastatic disease and c)
disease progression on the prior systemic regimen,

4. Must have received at least 2 prior systemic therapies approved for mCRPC

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

6. Adequate bone marrow function, including:

7. Able to read, understand and provide written informed consent

Key Exclusion Criteria:

1. Untreated brain metastases. Participants must have completed treatment for brain
metastasis, and be neurologically stable off steroids, for at least 4 weeks prior to
first dose of study drug.

2. Untreated spinal cord compression. Participants must be neurologically stable off
steroids for at least 4 weeks prior to first dose of study drug.

3. Concurrent treatment with anti-tumor necrosis factor (TNF) alpha therapies, systemic
corticosteroids (prednisone dose >10 mg per day or equivalent), or other immune
suppressive drugs within the 2 weeks prior to Screening

4. History of or known or suspected autoimmune disease (exception(s): patients with
vitiligo, resolved childhood atopic dermatitis, hypothyroidism, or hyperthyroidism
that is clinically euthyroid at Screening are allowed)

5. History of clinically significant cardiovascular disease

6. Active or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B surface
antigen (HBsAg) positivity and/or anti-hepatitis C virus (HCV) positivity,
respectively, or known history of human immunodeficiency virus (HIV) seropositive
status

7. Clinically active or chronic liver disease,

8. Second primary malignancy that has not been in remission for greater than 3 years.
We found this trial at
2
sites
New York, New York 10032
Phone: 212-304-5543
?
mi
from
New York, NY
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials